Inflammation and arthritis: Perspectives of the glycobiologist

Expert Review of Clinical Immunology

Volumn 4, Issue 2, 2008, Pages 173-191

  Brockhausen, Inka ^a   Anastassiades, Tassos P ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Advanced glycation end product; Arthritis; Bone; Cartilage; Collagen; Glucosamine; Glycoprotein; Glycosylation; Inflammation

Indexed keywords

ADALIMUMAB; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALENDRONIC ACID; BACTERIAL POLYSACCHARIDE; BINDING PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; COLLAGEN; EPITOPE; ESTROGEN; ETANERCEPT; FIBRONECTIN; GALECTIN; GLUCOSAMINE; GLYCAN; GLYCOPROTEIN; GLYCOSYLTRANSFERASE; GLYCOSYLTRANSFERASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; HEXOSAMINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INFLIXIMAB; OROSOMUCOID; PAMIDRONIC ACID; RISEDRONIC ACID; SELECTIN; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ACYLATION; ADAPTIVE IMMUNITY; ARTHRITIS; AUTOIMMUNE DISEASE; BONE REMODELING; BONE TURNOVER; CARBOHYDRATE ANALYSIS; CARTILAGE DEGENERATION; CELL TRANSPORT; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; IMAGING SYSTEM; IMMUNOREGULATION; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; JOINT DEGENERATION; LEUKOCYTE; NONHUMAN; OSTEOARTHRITIS; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 46149101455     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.2.173     Document Type: Review

References (150)

1. Schett G. Rheumatoid arthritis: inflammation and bone loss. Wien. Med. Wochenschr. 156, 34-41 (2006).
2. Xu C, Oyajobi BO, Frazer A, Kozaci LD, Russell RG, Hollander AP. Effects of growth factors and interleukin-1 α on proteoglycan and type II collagen turnover in bovine nasal and articular chondrocyte pellet cultures. Endocrinology 137, 3557-3565 (1996).
3. Lum ZP, Hakala BE, Mort JS, Recklies AD. Modulation of the catabolic effects of interleukin-1 β on human articular chondrocytes by transforming growth factor-β. J. Cell Physiol. 166,351-359 (1996).
4. Yang X, Lehotay M, Anastassiades T, Harrison M, Brockhausen I. The effect of TNFα on glycosylation pathways in bovine synoviocytes. Biochem. Cell Biol. 82(5), 559-568 (2004).
5. Yang X, Yip J, Anastassiades T, Harrison M, Brockhausen I. The action of TNFα and TGFβ include specific alterations of the glycosylation of bovine and human chondrocytes. Biochim. Biophys. Acta 1773(2), 264-272 (2006).
6. Yang X, Yip J, Harrison M, Brockhausen I. Primary human osteoblasts and bone cancer cells as models to study glycodynamics in bone. Int. J. Biochem. Cell Biol. 40(3), 471-483 (2008).
7. Homandberg GA. Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments. Front. Biosci. 154, D713-D739 (1999).
8. Opdenakker G, Dillen C, Fiten P et al. Remnant epitopes, autoimmunity and glycosylation. Biochim. Biophys. Acta. 1760, 610-615 (2006).
9. Lasky LA, Singer MS, Dowbenko, D et al. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell 69, 927-938 (1992).
10. Tsuboi S, Fukuda M. Roles of O-linked oligosaccharides in immune responses. Bioessays 23, 46-53 (2001)
11. Funderburgh JL. Keratan sulfate: structure, biosynthesis, and function. Glycobiology 10, 951-958 (2000).
12. Wakitani S, Nawata M, Kawaguchi A et al. Serum keratan sulfate is a promising marker of early articular cartilage breakdown. Rheumatology (Oxjord) 46, 1652-1656 (2007).
13. Midura RJ, Hascall VC. Bone sialoprotein - a mucin in disguise? Glycobiology 677-681 (1996).
14. Li Y, Yang X, Nguyen A, Brockhausen I. Requirement of N-glycosylation for the secretion of recombinant extracellular domain ofhuman Fas in HeLa cells. Int. J. Biochem. Cell Biol. 39, 1625-1636 (2007).
15. Middleton-Hardie C, Zhu Q, Cundy H et al. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J. Bone Miner. Res. 21, 438-445 (2006).
16. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 9, S1-S7 (2007).
17. Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-κB ligand and their differential expression in bone and thymus. Endocrinology 142, 1419-1426 (2001).
18. Nakamura I, Duong le T, Rodan SB, Rodan GA. Involvement of α(v)β3 integrins in osteoclast function. J. Bone Miner. Metab. 25, 337-344 (2007).
19. Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj. J. 21, 9-15 (2004).
20. Suda T, Nagata S. Why do defects in the Fas - Fas ligand system cause autoimmunity? J. Allergy Clin. Immunol. 100, S97-S101 (1997).
21. Matsuno H, Yudoh K, Nakazawa F et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/ SCID mouse chimera. J. Rheumatol. 29, 1609-1614 (2002).
22. Brockhausen I, Lehotay M, Yang JM et al. Glycoprotein biosynthesis in porcine aortic endothelial cells and changes in the apoptotic cell population. Glycobiology 12, 33-45 (2002).
23. Garcia-Vallejo JJ, Van Dijk W, Van Het Hof B et al. Activation of human endothelial cells by tumor necrosis factor-α results in profound changes in the expression of glycosylation-related genes. J. Cell. Physiol. 206(1), 203-210 (2006).
24. Tian F, Hagen KG, Shum L et al. An inhibitor of O-glycosylation induces apoptosis in NIH3T3 cells and developing mouse embryonic mandibular tissues. J. Biol. Chem. 279, 50382-50390 (2004).
25. Moreland LW, Heck LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 40, 397-409 (1997).
26. Lowe JB. Glycosylation, immunity, and autoinimunity. Cell 104, 809-812 (2001).
27. Fukuda M. Role of mucin-type O-glycans in cell adhesion. Biochim. Biophys. Acta 1573, 394-405 (2002).
28. Brockhausen I. The role of galactosyltransferases in cell surface functions and in the immune system. Drug News Perspect. 19(7), 401-409 (2006).
29. Takahashi K, Ezekowitz RA. The role of the mannose-binding lectin in innate immunity. Clin. Infect. Dis. 41, S440-444 (2005).
30. Buzás EI, György B, Pásztói M, Jelinek I, Falus A, Gabius HJ. Carbohydrate recognition systems in autoimmunity. Autoimmunity 39(8), 691-704 (2006).
31. Valladeau J, Duvert-Frances V, Pin JJ et al. Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J. Immunol. 167(10), 5767-5774 (2001).
32. Aarnoudse CA, Garcia Vallejo JJ, Saeland F, van Kooyk Y. Recognition of tumor glycans by antigen-presenting cells. Curr. Opin. Immunol. 18(1), 105-111 (2006).
33. van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J. Exp. Med. 201, 1281-1292 (2005).
34. Aarnoudse CA, Bax M, Sánchez-Hernández M, García-Vallejo JJ, van Kooyk Y. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells. Int. J. Cancer 122, 839-846 (2008).
35. García-Vallejo JJ, van Liempt E, da Costa Martins P et al. DC-SIGN mediates adhesion and rolling of dendritic cells on primary human umbilical vein endothelial cells through Lewis(Y) antigen expressed on ICAM-2. Mol. Immunol. DOI:10.1016/ j.molimm.2007.11.001 (2007) (Epub ahead of print).
36. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5. Nature 409(6821), 733-739 (2001).
37. Dennis JW, Pawling J, Cheung P, Partridge E, Demetriou M. UDP-N-acetylglucosamine: α-6-D-mannoside β1,6-N-acetylglucosaminyltransferase V (MgatV) deficient mice. Biochim. Biophys. Acta 1573(3), 414-422 (2002).
38. Chui D, Sellakumar G, Green RS et al. Genetic remodeling of protein glycosylation in vivo induces autoimmune disease. Proc. Natl Acad. Sci. USA 98, 1142-1147 (2001).
39. Green RS, Stone EL, Tenno M, Lehtonen E, Farquhar MG, Marth JD. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity 27, 308-320 (2007)
40. Walter S, Fassbender K, Gulbins E et al. Glycosylation processing inhibition by castanospermine prevents experimental autoimmune encephalomyelitis by interference with IL-2 receptor signal transduction. J. Neuroimmunol. 132(1-2), 1-10 (2002).
41. Grabie N, Delfs MW, Lim YC, Westrich JR, Luscinskas FW, Lichtman AH. β-galactoside α2,3-sialyltransferase-I gene expression during Th2 but not Th1 differentiation: implications for core 2-glycan formation on cell surface proteins. Eur. J. Immunol. 32, 2766-2772 (2002)
42. + T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity 12(3), 273-283 (2000).
43. + T-cell apoprosis. Mol. Cell. Biol. 27(3), 1096-1111 (2007).
44. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7(4), 255-266 (2007).
45. Crocker PR. Siglecs in innate immunity. Curr. Opin. Pharmacol. 5, 431-437 (2005).
46. Grewal PK, Boron M, Ramirez K et al. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol. Cell. Biol. 26(13) 4970-4981 (2006).
47. + T cell responses. J. Immunol. 173, 275-284 (2004).
48. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
49. Kannagi R. Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr. Opin. Struct. Biol. 12(5), 599-608 (2002).
50. Yang J, Rosen SD, Bendele P, Hemmerich S. Induction of PNAd and N-acetylglucosamine 6-O-sulfotransferases 1 and 2 in mouse collagen-induced arthritis. BMC Immunol. 7, 12 (2006).
51. Pablos JL, Santiago B, Tsay D et al. A HEV-restricted sulfatransferase is expressed in rheumatoid arthritis synovium and is induced by lymphotoxin-α/β and TNF-α in cultured endothelial cells. BMC Immunol. 6, 6 (2005).
52. Asano M, Nakae S, Kotani N et al. Impaired selectin-ligand biosynthesis and reduced inflammatory responses in β-1,4-galactosyltransferase-I-deficient mice. Blood 102(5), 1678-1685 (2003).
53. Mori R, Kondo T, Nishie T, Ohshima T, Asano M. Impairment of skin wound healing in β-1,4-galactosyltransferase-deficient mice with reduced leukocyte recruitment. Am. J. Pathol. 164 (4), 1303-1314 (2004).
54. Ellies LG, Sperandio M, Underhill GH et al. Sialyltransferase specificity in selectin ligand formation. Blood 100, 3618-3625 (2002).
55. Martinez M, Joffraud M, Giraud S et al. Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII. J. Biol. Chem. 280, 5378-5390 (2005).
56. Lowe JB. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr. Opin. Cell Biol. 15, 531-538 (2003).
57. Ellies LG, Tsuboi S, Petryniak B, Lowe JB, Fukuda M, Marth JD. Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation. Immunity 9, 881-890 (1998).
58. Toscano MA, Bianco GA, Ilarregui JM et al. Differential glycosylation of Th1, Th2 and Th17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8(8), 825-834 (2007).
59. Nakagawa H, Hato M, Takegawa Y et al. Detection of altered N-glycan profiles in whole serum from rheumatoid arthritis patients. J. Chromatogr. 853(1-2), 133-137 (2007).
60. Smith KD, Pollacchi A, Field M, Watson J. The heterogeneity of the glycosylation of α-1-acid glycoprotein between the sera and synovial fluid in rheumatoid arthritis. Biomed. Chromatogr. 16, 261-266 (2002).
61. Haston JL, FitzGerald O, Kane D, Smith KD. Preliminary observations on the influence of rheumatoid α-1-acid glycoprotein on collagen fibril formation. Biomed. Chromatogr. 16, 332-342 (2002).
62. Ferens-Sieczkowska M, Kossowska B, Gancarz R et al. Fucosylation in synovial fluid as a novel clinical marker for differentiating joint diseases - a preliminary study Clin. Exp. Rheumatol. 25(1), 92-95 (2007).
63. Mimura Y, Sondermann P, Ghirlando R et al. Role of oligosaccharide residues of IgG1-Fc in Fc γ RIIb binding. J. Biol. Chem. 276, 45539-45547 (2001).
64. Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, Gindzienski A, Sierakowski S. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin. Rheumatol. 26(5), 685-690 (2007).
65. Kuroda Y, Nakata M, Hirose S et al. Abnormal IgG galactosylation in MRL-lpr/lpr mice: pathogenic role in the development of arthritis. Pathol. Int. 51, 909-915 (2001).
66. Alavi A, Pool AJ, Axford JS. New insights into rheumatoid arthritis associated glycosylation changes. Adv. Exp. Med. Biol. 564, 129-138 (2005).
67. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl Acad. Sci. USA 104, 8433-8437 (2007).
68. Alavi A, Axford JS, Pool AJ. Serum galactosyltransferase isoforin changes in rheumatoid arthritis. J. Rheumatol. 31(8), 1513-1520 (2004).
69. Carsons S. Enhanced expression of a peanut agglutinin reactive O linked oligosaccharide on fibronectins from the synovial fluid of patients with rheumatic disease: quantitation, domain localization, and functional significance. J. Rheumatol. 29(5), 896-902 (2002).
70. Rees-Milton KJ, Terry D, Anastassiades TP. Hyperglycosylation of fibronectin by TGF-β1 -stimulated chondrocytes. Biochem. Biophys. Res. Commun. 317(3), 844-850 (2004).
71. Haubeck HD, Kock R, Fischer DC, Van de Leur E, Hoffmeister Y, Greiling H. Transforming growth factor β 1, a major stimulator of hyaluronan synthesis in human synovial lining cells. Arthritis Rheum. 38, 669-677 (1995).
72. Giasuddin AS, Hoque ME, Ahmed ZU. Tumour necrosis factor-α as a new therapeutic target for rheumatoid arthritis: an update. Bangladesh Med. Res. Counc. Bull. 31, 88-94 (2005).
73. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand. J. Rheumatol. 36,411-417 (2007).
74. Rabinovich GA, Gruppi A. Galectins as immunoregulators during infectious processes: from microbial invasion to the resolution of the disease. Parasite Immunol. 27, 103-114 (2005).
75. Liu FT. Galectins: novel anti-inflammatory drug targets. Expert Opin. Ther. Targets 6, 461-468 (2002).
76. Janelle-Montcalm A, Boileau C, Poirier F et al. Extracellular localization of galectin-3 has a deleterious role in joint tissues. Arthritis Res. Ther. 9(1), R20 (2007).
77. Rabinovich GA, Toscano MA, Ilarregui JM, Rubinstein N. Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses. Glycoconj. J. 19, 565-573 (2004).
78. Chen HY, Liu FT, Yang RY. Roles of galectin-3 in immune responses. Arch. Immunol. Ther. Exp. (Warsz.) 53, 497-504 (2005).
79. Ohshima S, Kuchen S, Seemayer CA et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 48, 2788-2795 (2003).
80. Guevremont M, Martel-Pelletier J, Boileau C et al. Galectin-3 surface expression on human adult chondrocytes: a potential substrate for collagenase-3. Ann. Rheum. Dis. 63(6), 636-643 (2004).
81. Ilarregui JM, Bianco GA, Toscano MA, Rabinovich GA. The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders. Ann. Rheum. Dis. 64, iv96-iv103 (2005).
82. Rabinovich GA, Daly G, Dreja H et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190, 385-397 (1999).
83. Ruotsalainen H, Sipilä L, Vapola. M et al. Glycosylation catalyzed by lysyl hydroxylase 3 is essential for basement membranes. J. Cell Sci. 119, 625-635 (2006).
84. Rautavuoma K, Takaluoma K et al. Characterization of three fragments that constitute the 4 monomers of the human lysyl hydroxylase isoenzymes 1-3. J. Biol. Chem. 277, 23084-23091 (2002).
85. Wang C, Luosujärvi H, Heikkinen J, Risteli M, Uitto L, Myllylä R. The third activity for lysyl hydroxylase 3: galactosylation of hydroxylysyl residues in collagens in vitro. Matrix Biol. 21, 559-566 (2002).
86. Holm L, Kjellén P, Holmdahl R, Kihlberg J. Identification of the minimal glycopeptide core recognized by T cells in a model for rheumatoid arthritis. Bioorg. Med. Chem. 13(2), 473-482 (2005).
87. Myers LK, Myllyharju J, Nokelainen M et al. Relevance of posttranslational modifications for the arthritogenicity of type II collagen. J. Immunol. 172(5), 2970-2975 (2004).
88. Dzhambazov B, Holmdahl M, Yamada H et al. The major T cell epitope on type 11 collagen is glycosylated in normal cartilage but modified by arthritis in both rats and human. Eur. J. Immunol. 35, 357-366 (2005).
89. Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. 176, 1525-1533 (2006).
90. von Delwig A, Altmann DM, Charlton FG et al. T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1 *0101 transgenic mice. Ann. Rheum. Dis. 66(5), 599-604 (2007).
91. Baecklund J, Carlsen S, Hoeger T et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 99(15), 9960-9965 (2002).
92. Lo Cascio V, Bertoldo F, Gambaro, G et al. Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: a potential marker of bone fragility. J. Bone Miner, Res. 14,1420-1424 (1999).
93. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13(17), 1971-1978 (2006).
94. Hein GE. Glycation endproducts in osteoporosis - is there a pathophysiologic importance? Clin. Chim. Acta 371, 32-36 (2006).
95. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42, 1242-1246 (2003).
96. Steenvoorden MM, Huizinga TW, Vcrzijl N et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum. 54(1), 253-263 (2006).
97. Miyata T, Motoya K, Yoshida K et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J. Am. Soc. Nephrol. 8(2), 260-270 (1997).
98. Srikrishna G, Huttunen HJ, Johansson L et al. N-glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J. Neurochem. 80, 998-1008 (2002).
99. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Makino H. increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum. 54(1) 97-104 (2006).
100. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum. 54(9), 2901-2911 (2006).
101. McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Nonenzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2, 16 (2001).
102. Drinda S, Franke S, Rüster M et al. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis: Rheumatol. Int. 25(6), 411-413 (2005).
103. Loeser RF, Yammani RR, Carlson CS et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum. 52(8), 2376-2385 (2005).
104. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther. 7(4), R817-R824 (2005).
105. Vahamiko S, Penttinen MA, Granfors K. Aetiology and pathogenesis of reactive arthritis: role of non-antigen-presenting effects of HLA-B27. Arthritis Res. Ther. 7(4), 136-141 (2005).
106. Inman RD. Mechanisms of disease: infection and spondyloarthritis. Nat. Clin. Pract. Rheumatol. 2(3), 163-169 (2006).
107. Hannu T, Inman R, Granfors K, Leirisalo-Repo M. Reactive arthritis or post-infectious arthritis? Best Pract. Res. Clin. Rheumatol. 20(3), 419-33 (2006).
108. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12(3), 167-181 (2005).
109. Lloyd DH, Viac J, Werling D, Rème CA, Gatto H. Role of sugars in surface microbe-host interactions and immune reaction modulation. Vet. Dermatol. 18, 197-204 (2007).
110. Yoshino S, Sasatomi E, Ohsawa M. Bacterial lipopolysaccharides acts as an adjuvant to induce autoimmune arthritis in mice. Immunology 99(4), 607-614 (2000).
111. Yoshino S, Ohsawa M. The role of lipopolysaccharide injected systemically in the reactivation of collagen-induced arthritis in mice. Br. J. Pharmacol. 129(7), 1309-1314 (2000).
112. Chen W, Jin W, Cook M, Weiner HL, Wahl SM. Oral delivery of group A streptococcal cell walls augments circulating TGFβ and suppresses streptococcal cell wall arthritis. J Immunol. 161(11), 6297-6304 (1998).
113. Kimpel D, Dayton T, Fuseler J et al. Splenectomy attenuates streptococcal cell wall-induced arthritis and alters leukocyte activation. Arthritis Rheum. 48(12), 3557-3567 (2003).
114. Koenders MI, Lubberts E, Oppers-Walgreen B et al. Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1. Arthritis Rheum. 52(3), 975-983 (2005).
115. Koenders MI, Lubberts E, van de Loo FA et al. Interleukin-17 acts independently of TNF-α under arthritic conditions. J. Immunol. 176(10), 6262-6269 (2006).
116. Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WC. GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann. Rheum. Dis. 66(4), 452-457 (2007).
117. Sandalon Z, Bruckheimer EM, Lustig KH, Burstein H. Long-term suppression of experimental arthritis following intramuscular administration of a pseudotyped AAV2/1-TNFR:Fc vector. Mol. Ther. 15(2), 264-269 (2007).
118. Durr HD, Martin H, Pellengahr C et al. The cause of subchondral bone cysts in osteoarthrosis: a finite element analysis. Acta Orthop. Scand. 75, 554-558 (2004).
119. Glass DA 2nd, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 148(6), 2630-2634 (2007).
120. Kurayoshi M, Yamamoto H, Izumi S, Kikuchi A. Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem. J. 402, 515-523 (2007).
121. Takahata M, Iwasaki N, Nakagawa H et al. Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone 41(1), 77-86 (2007).
122. Carbone LD, Nevitt MC, Wildy K et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 50, 3516-3525 (2004).
123. Bingham CO 3rd, Buckland-Wright JC, Garnero P et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 54(11), 3494-3507 (2006).
124. Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 46(2), 257-264 (2007).
125. Anastassiades T, Rees-Milton K. Biochemical markers for osteoarthritis: from the present to the future and back to the past. J. Rheumatol. 32(4), 578-579 (2005).
126. Breuil V, Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73(4), 349-354 (2006).
127. Haynes DR, Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. Inflammopharmacology 14(5-6), 193-197 (2006).
128. Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented? Rheum Dis. Clin. North Am. 32(4), 759-773 (2006).
129. Boulos P, Dougados M, Macleod SM, Hunsche E. Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 65(15), 2111-2127 (2005).
130. Felson DT. Kim YJ. The futility of current approaches to chondroprotection. Arthritis Rheum. 56(5), 1378-1383, (2007).
131. Hopman WM, Towheed TE, Gao Y et al. Prevalence of and factors associated with glucosamine use in Canada. Osteoarthr. Cartil. 14(12), 1288-1293 (2006).
132. Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AH. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum. 52(1), 181-191 (2005).
133. Persiani S, Roda. E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr. Cartil. 13(12), 1041-1049 (2005).
134. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthr. Cartil. 11, 424-432 (2003).
135. Largo R, Alvarez-Soria MA, Diez-Ortego I et al. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthr. Cartil. 11, 290-298 (2003).
136. Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin. Exp. Rheumatol. 22, 293-299 (2004).
137. Varghese S, Theprungsirikul P. Sahani S, Hwang N, Yarema KJ, Elisseeff JH. Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthr. Cartil. 15, 59-68 (2007).
138. Terry DE, Rees-Milton K, Pruss C, Hopwood J, Carran J, Anastassiades TP. Modulation of articular chondrocyce proliferation and anionic glycoconjugate synthesis by glucosamine (GlcN), N-acetyl GlcN (GlcNAc) GlcN sulfate salt (GlcN.S) and covalent glucosamine sulfates (GlcN-SO(4)) Osteoarthr. Cartil. 15(8), 946-956 (2007).
139. Nelson BA, Robinson KA, Buse MG. High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes. Diabetes 49(6), 981-991 (2000).
140. D'Lima DD, Kuhn K, Lotz MK. Detection of apoptosis in cartilage in situ and in isolated chondrocytes. In: Methods in Molecular Medicine: Cartilage and Osteoarthritis. Volume 1: Cellular and Molecular Tools. Sabatini M, Pastoureau P, DeCeuninck F (Eds). Humana Press Inc. NJ, USA 275-289 (2004).
141. Uitterlinden EJ, Jahr H, Koevoet JL et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthr. Cartil. 14, 250-257 (2006).
142. Towheed TE, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst. Rev. 18(2), CD002946 (2005).
143. McAlindon TE. Nutraceuticals: do they work and when should we use them? Best Pract. Res. Clin. Rheumatol. 20, 99-115 (2006).
144. Cibere J, Kopec JA, Thorne A et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum. 51, 738-745 (2004).
145. Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 354, 795-808 (2006).
146. Terry DE, Rees-Milton K, Smith P et al. N-acylation of glucosamine modulates chondrocyte growth, proteoglycan synthesis, and gene expression. J. Rheumatol. 32, 1775-1786 (2005).
147. Wang SX, Cherian A, Dumitriu M et al. Disease modifying effects of N-butyryl glucosamine in a streptococcal cell wall induced arthritis model in rats. J. Rheumatol. 34(4), 712-720 (2007).
148. Brockhausen I, Carran J, McElleney K et al. N-acyl derivatives of glucosamine as acceptor substrates for galactosyltransferase from bone and cartilage cells. Carbohydr. Res. 340, 1997-2003 (2005).
149. Brockhausen I, Benn M, Bhat S et al. UDP-Gal: GlcNAc-R 1,4-galactosyltransferase - a target enzyme for drug design. Acceptor specificity and inhibition of the enzyme. Glycoconj. J. 23, 523-539 (2006).
150. Liang PH, Cheng WC, Lee YL et al. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis. Chembiochem 7, 165-173 (2006).